ATS 2020 Advance Program

created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDGene are to identify new genetic loci that influence the development of COPD and COPD-related phenotypes; and to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. Presenters will discuss new results from the COPDGene study, including new ways to diagnose the disease, deep learning approaches to imaging data, genetics, epigenetics, transcriptomics, proteomics, and an integrative Omics approach. Chairing: L. Postow, PhD, Bethesda, MD J.D. Crapo, MD, Denver, CO E.K. Silverman, MD, PhD, Boston, MA 12:15 New Approaches to COPD Diagnosis and Progression K.A. Young, MSPH, PhD, Aurora, CO 12:27 Imaging and Deep Learning S.M. Humphries, PhD, MS, Denver, CO 12:39 Updates on Genetics and Epigenetics M. Moll, MD, Boston, MA 12:51 Applications of Transcriptomics and Proteomics P. Castaldi, MD, MSc, Boston, MA 1:03 Using Integrative Omics to Understand COPD Pathobiology and Heterogeneity B.D. Hobbs, MD, Boston, MA DIVISION OF LUNG DISEASES/NHLBI L9 THE PEDIATRIC PULMONARY VASCULAR DISEASE (PVD) REGISTRY: METHODS, RESULTS AND IMPLICATIONS 12:15 p.m. - 1:15 p.m. Target Audience Pediatric pulmonologists, pediatric cardiologists, neonatologists, pediatric critical care, epidemiologists, as well as informatics and artificial intelligence experts. Objectives At the conclusion of this session, the participant will be able to: • utilize electronic health records to create a registry; • understand characterization and comprehensive phenotyping of pediatric pulmonary hypertension; • learn statistical analysis of large datasets. Pediatric pulmonary hypertension (PH) contributes to high morbidity and mortality in children with diverse lung, heart and systemic diseases, yet major gaps in our understanding of its natural history, pathobiology, diagnostic approaches and therapy persist. Despite sharing similarities with adult disease, many aspects of pediatric PH are distinct from adult PH, as childhood PH is intrinsically linked to issues of lung growth and development,and associated with unique diseases of childhood and has apparent differences in responsiveness to therapies. Thus, pediatric PH has been largely understudied and much remains poorly understood regarding its epidemiology, long-term outcomes and approaches for care. Chairing: S.H. Abman, MD, Aurora, CO K. Mandl, MD, PhD, Boston, MA A. Natarajan, MD, PhD, Bethesda, MD 12:15 Introduction K. Mandl, MD, PhD, Boston, MA 12:20 Classification of Pediatric Pulmonary Hypertensive Disorders from the PPHNet Registry M. Mullen, MD, PhD, Cambridge, MA 12:30 Computable Phenotyping Opportunities for Pediatric Pulmonary Hypertension A. Geva, MD, Boston, MA 12:40 Racial and Ethnic Diversity in Pediatric PH M.-S. Ong, PhD, Boston, MA 12:50 TBX4 and Severe PH in Developmental Neonatal Lung Disorders C. Galambos, MD, PhD, Aurora, CO 1:00 Hemodynamic Profile of Pediatric PH E.B. Rosenzweig, MD, New York, NY 1:10 Questions and Answers A. Natarajan, MD, PhD, Bethesda, MD ATS 2020 • Philadelphia, PA 52 SUNDAY • MAY 17